The objectives were to develop a solid oral 600 mg ALA FSP to obtain an optimal pharmaceutical profile compared to a reference listed drug (RLD) with a similarity factor f2 > 50. A comparative dissolution study was performed; an HPLC method was used for ALA quantification. After planning ...